Oruka Therapeutics Inc (ORKA) Stock Price, Quote & News

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. T...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 606 7910

Website: orukatx.com

Address:

855 Oak Grove Avenue, Suite 100, Menlo Park, United States

Nosh Apr. 7 at 9:44 PM

$ORKA In at under $60...MAY add let's see.

0 · Reply

erevnon Apr. 7 at 8:30 PM

Barclays maintains Oruka Therapeutics $ORKA at Overweight and raises the price target from $50 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

blessme1 Apr. 7 at 7:37 PM

$ORKA pretty close was off by a couple of days 🤝🔥

0 · Reply

outlawinvestor1 Apr. 7 at 5:03 PM

$ORKA seems to be trading as if a buyout is coming. 🤔 in any case, i will be selling half of my position in early may, just ahead of the orka-001 16 week readout. this seems fairly derisked, but there's always the possibility for surprises.

0 · Reply

Astrobro Apr. 7 at 5:01 PM

$ORKA 3B+ MC for a ph2 company lol, this thing is about to TIMBERRR.

1 · Reply

Pika_Capital Apr. 7 at 4:59 PM

$ORKA what a run. Selling here a nice chunk

1 · Reply

Whiskeyunderthebed Apr. 6 at 5:12 PM

$ORKA new buyers stepping in-

0 · Reply

NeverFadeTheOracle Apr. 6 at 2:43 PM

$ORKA Guggenheim Price Target 125 From 60 https://www.investing.com/news/analyst-ratings/guggenheim-raises-oruka-therapeutics-price-target-on-trial-outlook-93CH-4598154

0 · Reply

WAJeff Apr. 6 at 1:35 PM

$ORKA Been on a tear

0 · Reply

anachartanalyst Apr. 6 at 12:02 PM

$ORKA https://anachart.com/wp-content/uploads/ana_temp/1775476870_soc-img.jpg

0 · Reply

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 9, 2026, 7:00 AM EST - 2 months ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Jan 12, 2026, 7:00 AM EST - 3 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 6, 2026, 7:00 AM EST - 3 months ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:01 PM EST - 4 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Nov 12, 2025, 4:05 PM EST - 5 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 7:00 AM EDT - 5 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Sep 17, 2025, 1:02 AM EDT - 7 months ago

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:00 AM EDT - 7 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Aug 11, 2025, 4:04 PM EDT - 8 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 21, 2025, 7:00 AM EDT - 9 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 1, 2025, 4:01 PM EDT - 10 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

May 21, 2025, 7:00 AM EDT - 11 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 11 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 14, 2025, 4:15 PM EDT - 11 months ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 12, 2024, 7:05 AM EDT - 1 year ago

Oruka Therapeutics Announces $200 Million Private Placement

Aug 29, 2024, 4:50 PM EDT - 1 year ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 26, 2024, 7:30 PM EDT - 1 year ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 1 year ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 1, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 6:34 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 25, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

Feb 24, 2023, 4:20 PM EST - 3 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Dec 19, 2022, 4:05 PM EST - 3 years ago

James Flynn Joins ARCA biopharma Board of Directors

Oct 28, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results

Aug 2, 2022, 4:15 PM EDT - 4 years ago

ARCA biopharma Announces Second Quarter 2022 Financial Results

Jun 21, 2022, 4:05 PM EDT - 4 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

May 5, 2022, 4:15 PM EDT - 4 years ago

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

May 2, 2022, 4:15 PM EDT - 4 years ago

ARCA biopharma Announces First Quarter 2022 Financial Results

Apr 18, 2022, 4:30 PM EDT - 4 years ago

ARCA biopharma Establishes Special Committee of the Board of Directors

Apr 1, 2022, 7:21 AM EDT - 4 years ago

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

Nosh Apr. 7 at 9:44 PM

$ORKA In at under $60...MAY add let's see.

0 · Reply

erevnon Apr. 7 at 8:30 PM

Barclays maintains Oruka Therapeutics $ORKA at Overweight and raises the price target from $50 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

blessme1 Apr. 7 at 7:37 PM

$ORKA pretty close was off by a couple of days 🤝🔥

0 · Reply

outlawinvestor1 Apr. 7 at 5:03 PM

0 · Reply

Astrobro Apr. 7 at 5:01 PM

$ORKA 3B+ MC for a ph2 company lol, this thing is about to TIMBERRR.

1 · Reply

Pika_Capital Apr. 7 at 4:59 PM

$ORKA what a run. Selling here a nice chunk

1 · Reply

Whiskeyunderthebed Apr. 6 at 5:12 PM

$ORKA new buyers stepping in-

0 · Reply

NeverFadeTheOracle Apr. 6 at 2:43 PM

$ORKA Guggenheim Price Target 125 From 60 https://www.investing.com/news/analyst-ratings/guggenheim-raises-oruka-therapeutics-price-target-on-trial-outlook-93CH-4598154

0 · Reply

WAJeff Apr. 6 at 1:35 PM

$ORKA Been on a tear

0 · Reply

anachartanalyst Apr. 6 at 12:02 PM

$ORKA https://anachart.com/wp-content/uploads/ana_temp/1775476870_soc-img.jpg

0 · Reply

erevnon Apr. 6 at 11:28 AM

Guggenheim maintains Oruka Therapeutics $ORKA at Buy and raises the price target from $60 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Quantumup Apr. 6 at 11:17 AM

Guggenheim⬆️ $ORKA's PT to $125 from $60 and reiterated at Buy. $ABBV $JNJ PTGX UCBJY Here's what Guggenheim had to say in its note: https://x.com/Quantumup1/status/2041111882489106643?s=20

0 · Reply

DonCorleone77 Apr. 6 at 10:40 AM

$ORKA $ABBV Oruka Therapeutics price target raised to $125 from $60 at Guggenheim Guggenheim raised the firm's price target on Oruka Therapeutics (ORKA) to $125 from $60 and keeps a Buy rating on the shares. Ahead of the Phase 2a EVERLAST-A study topline data readout in Q2, the firm says its base-case assumes ORKA-001 efficacy on par with AbbVie's (ABBV) Skyrizi but adds that it thinks there is a real potential for ORKA-001 to produce efficacy that is superior to Skyrizi given the dose exposure relationship with Skyrizi.

0 · Reply

CamdenSignals Apr. 3 at 7:22 PM

$ETON — broke out of a 4 month consolidation. Relative strength vs SPY is strong. Watching $25.99 for continuation. $GSAT — holding up way better than the broader market. Want to see if it can clear $78. $INTC — above the 21 EMA with a golden cross still intact. $50.49 is the level. $ORKA — quietly holding gains while everything else sells off. $APLS — structure tightening. Could go either way but the compression is worth watching. Market is still in rough shape so I’m not chasing anything. Just mapping levels for when conditions improve. What’s everyone else watching?

0 · Reply

NeverFadeTheOracle Apr. 2 at 3:10 PM

$ORKA $XBI Another 52-week high

0 · Reply

Astrobro Apr. 2 at 12:09 AM

$ORKA a 3B FD MC for...two barely ph2 mABs? Holy short.

0 · Reply

blessme1 Apr. 1 at 1:56 PM

$ORKA a couple days late on the 50 but it's here. Let's head to 54 then 60 💪🤝

0 · Reply

NeverFadeTheOracle Mar. 31 at 11:40 PM

$ORKA $XBI What a beast

0 · Reply

WAJeff Mar. 31 at 5:01 PM

$ORKA 3/26 46.09s sold at 49, new 52 week high

1 · Reply

thesheiktrader Mar. 31 at 4:44 PM

$MLTX $ORKA the really diamonds

0 · Reply

blessme1 Mar. 27 at 12:49 PM

$ORKA touch 50 today, then next week 60 or drop some news for a halt up 📈

0 · Reply

thesheiktrader Mar. 26 at 2:12 PM

$ORKA I’m tired to say, this stock will skyrocket until 80-90. Catch now is Free money

0 · Reply

Market Cap	2.64B
Revenue (ttm)	0.00
Net Income (ttm)	-105.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,413,732
Avg Vol	592,552
Day's Range	N/A - N/A
Shares Out	49.54M
Stochastic %K	87%
Beta	-0.54
Analysts	Strong Sell
Price Target	$63.00